FUJIFILM Invests £400M to Expand Biomanufacturing and Process Development Capacity

Introduction

FUJIFILM Biotechnologies, a global contract development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, has expanded its site in Teesside, UK, with a total investment of approximately £400 million from FUJIFILM Corporation, Japan. The expansion includes the UK’s largest single-use biopharmaceutical CDMO facility and a new Bioprocess Innovation Centre, enhancing the company’s global manufacturing and development capabilities.

Features

The site introduces 2,000 L and 5,000 L single-use bioreactors, with total capacity up to 19,000 L, supporting small- and mid-scale antibody production.

The Bioprocess Innovation Centre UK provides advanced laboratories for high-throughput and continuous process development.

The expansion doubles the existing laboratory footprint and complements Good Manufacturing Practice manufacturing capabilities.

Sustainability measures include a fully electrified manufacturing building and maximised use of renewable energy.

The facility will enhance supply chain flexibility, speed to market, and scalability for partners developing complex medicines for cancer, rare disorders, and neurodegenerative diseases.

The new manufacturing and process development facilities are expected to be fully operational in the first half of 2026.

Specifications: